Abstract: Objective : To observe the effect of capecitabine (xeloda) and related adverse effects in treatment of senile advanced colon and rectal carcinoma. Methods : By prospective random control trial,61 patients with senile advanced colon and rectal carcinoma who were admitted in Department of On-cology,General Hospital of Shenyang Military Region and the First Department of Internal Medicine,Liaoning Provincial Tumour Hospital were randomly divided into treatment group (n =30),treated by Capecitabine and Aidi injection;and control group (n=31),treated by Aidi injection simply.Two cycles later,evaluation was carried out. Results : Twenty-five indexes were evaluated and the effective rate (CR+PR) was 36.0%,in control group,24 indexes were evaluated and the effective rate (CR+PR) was 16.7%.There was a significant difference(P<0.05).In treatment group,5 patients presented with diarrea of over grade I,3 patients presented with nausea,vomitting of gradeⅠ~Ⅱ,2 patients with bone marrow depression of grade I,4 patients with hand-foot syndrome of gradeⅠ~Ⅱ.All these symptoms disap-peared after treatments to symptoms and no one gave up for adverse effects of drugs.In control group,2 patients presented with gastrointestinal reaction of over grade I,no obvious diarrhea,hand-foot syndrome and bone marrow depression were found.There were no treatment-related death in two groups. Conclusions : Capecitabine is the new generation of targeted 5-FU which is administrated by mouth and absorbed completely in gastrointestinal mucosa after activated by the TPase in tumor tissue.Capecitabine releases 5-FU in tumor tissues and develops its anti-cancer effect.The adverse effects were mild and patients could tolerate,so this therapeutic method is suitable to patients with senile advanced colonic and rectal carcinoma without indications of chemotherapy of vein and ineffective to 5-FU.